Onesource Specialty Pharma Appoints New Senior Management Personnel; Ravi Kumar Resigns
Onesource Specialty Pharma Ltd has announced changes in its Senior Management Personnel (SMP). Preeti Kalra has been designated as a new SMP, effective July 24, 2026, while Ravi Kumar resigned from his position, also effective on the same date.The designation of Ms. Preeti Kalra comes with an extensive background spanning over 25 years across various sectors including Biopharma, Global Development (Not-for-Profit), Public Services, and Insurance. Her leadership experience includes organizations such as Stelis Biopharm, Bill & Melinda Gates Foundation, Serco, and Ernst & Young.
Ms. Kalra's expertise lies in business partnering, talent management, organizational transformation, culture development, and change management. She has a proven track record of building high-performing teams and driving organizational effectiveness across the Asia-Pacific, Middle East, Africa, Europe, and North America regions.
Key details regarding Ms. Kalra’s profile are provided below:
| Particulars | Details |
|---|---|
| Reason for change | Designated as Senior Management Personnel |
| Date of cessation | Not Applicable |
| Brief professional profile | HR leader with 25+ years of experience across Biopharma, Global Development (Not-for-Profit), Public Services, Insurance, GCC and IT. Expertise includes organizational transformation, leadership development, and culture building. |
The company also confirmed the resignation of Ravi Kumar from his role as Senior Management Personnel. Mr. Kumar held the position of Global Head - Injectables/ Head of Corporate Strategy, Portfolio, and SPO.
ONESOURCE Stock Price Movement
Onesource Specialty Pharma Limited shares slipped by 0.32% on Friday, closing at ₹1653.9 after shedding ₹5.30 from the previous close. The stock traded a volume of 87,251 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.